Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSabaté Gallego, Mònica
dc.contributor.authorVidal Guitart, Xavier
dc.contributor.authorBallarin Alins, Maria Elena
dc.contributor.authorRottenkolber, M.
dc.contributor.authorSchmied, S.
dc.contributor.authorGrave, B.
dc.contributor.authorIbañez Mora, Luisa
dc.date.accessioned2022-05-31T09:06:46Z
dc.date.available2022-05-31T09:06:46Z
dc.date.issued2021-11
dc.identifier.citationSabaté M, Vidal X, Ballarin E, Rottenkolber M, Schmiedl S, Grave B, et al. Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015). Front Pharmacol. 2021 Nov;12:682890.
dc.identifier.issn1663-9812
dc.identifier.urihttp://hdl.handle.net/11351/7604
dc.descriptionAnticoagulants; Europe; Non valvular atrial fibrillation
dc.description.abstractAims: To describe and compare the adherence to different direct oral anticoagulants (DOACs) in eight European databases representing six countries. Methods: Longitudinal drug utilization study of new users (≥18 years) of DOACs (dabigatran, rivaroxaban, apixaban) with a diagnosis of non-valvular atrial fibrillation (2008–2015). Adherence was examined by estimating persistence, switching, and discontinuation rates at 12 months. Primary non-adherence was estimated in BIFAP and SIDIAP databases. Results: The highest persistence rate was seen for apixaban in the CPRD database (81%) and the lowest for dabigatran in the Mondriaan database (22%). The switching rate for all DOACs ranged from 2.4 to 13.1% (Mondriaan and EGB databases, respectively). Dabigatran had the highest switching rate from 5.0 to 20.0% (Mondriaan and EGB databases, respectively). The discontinuation rate for all DOACs ranged from 16.0 to 63.9% (CPRD and Bavarian CD databases, respectively). Dabigatran had the highest rate of discontinuers, except in the Bavarian CD and AOK NORDWEST databases, ranging from 23.2 to 64.6% (CPRD and Mondriaan databases, respectively). Combined primary non-adherence for examined DOACs was 11.1% in BIFAP and 14.0% in SIDIAP. There were differences in population coverage and in the type of drug data source among the databases. Conclusion: Despite the differences in the characteristics of the databases and in demographic and baseline characteristics of the included population that could explain some of the observed discrepancies, we can observe a similar pattern throughout the databases. Apixaban was the DOAC with the highest persistence. Dabigatran had the highest proportion of discontinuers and switchers at 12 months in most databases (EMA/2015/27/PH).
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Pharmacology;12
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMedicació oral
dc.subjectFibril·lació auricular - Tractament
dc.subjectMedicaments - Ús
dc.subject.meshAtrial Fibrillation
dc.subject.mesh/drug therapy
dc.subject.meshDrug Utilization
dc.subject.meshAdministration, Oral
dc.titleAdherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008–2015)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fphar.2021.682890
dc.subject.decsfibrilación atrial
dc.subject.decs/farmacoterapia
dc.subject.decsutilización de medicamentos
dc.subject.decsadministración oral
dc.relation.publishversionhttps://doi.org/10.3389/fphar.2021.682890
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Sabaté M, Vidal X, Ibáñez L] Fundació Institut Català de Farmacologia (FICF), Barcelona, Spain. Servei de Farmacologia Clínica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Farmacologia, Toxicologia i Terapèutica, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ballarin E] Fundació Institut Català de Farmacologia (FICF), Barcelona, Spain. Servei de Farmacologia Clínica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Rottenkolber M] Diabetes Research Group, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany. [Schmiedl S] Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany. Philipp Klee-Institute for Clinical Pharmacology, Helios University Hospital Wuppertal, Wuppertal, Germany. [Grave B] AOK NORDWEST, Dortmund, Germany
dc.identifier.pmid34803665
dc.identifier.wos000720117800001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record